T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023
T2 Biosystems to report Q3 2023 financial results and business updates
Positive
Investors can listen to the conference call for T2 Biosystems' preliminary financial results for Q3 2023 and business updates on October 12, 2023. The company is a leader in rapid detection of sepsis-causing pathogens and antibiotic resistance genes.
10/05/2023 - 04:05 PM
LEXINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report preliminary financial results for the third quarter 2023 and business updates after market close on Thursday, October 12, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com , on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 505931, approximately ten to five minutes prior to the start time.
About T2 Biosystems ® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, the T2Biothreat™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR® ) technology. T2 Biosystems has an active pipeline of future products, including the Acinetobacter baumannii test, the Candida auris test , and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information, please visit www.t2biosystems.com
Investor Contact:
T2 Biosystems will report its Q3 2023 financial results on October 12, 2023.
T2 Biosystems specializes in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.
Investors can listen to the conference call by accessing a live and archived webcast of the event on T2 Biosystems' website or by dialing the provided phone numbers.
TTOO Rankings
#5524 Ranked by Stock Gains
TTOO Stock Data
Industry
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Country
US
City
Lexington
About TTOO
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
